Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
About J&J
Our Credo
Our Leadership Team
Corporate Governance
Diversity & Inclusion
Empowering Women
Innovation at J&J
Office of the Chief Medical Officer
J&J Health and Wellness Solutions
Policies & Statements
Code of Business Conduct
Corporate Reports
Products
Consumer Products
Medical Devices
Pharmaceutical Products
Procurement
Value Pillars
Supplier Diversity
Supplier Standards
Careers
What We Do
How We Hire
Job Spotlight
Employee Benefits
Students
Innovation
Career Stories
Media Center
Investors
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2016 Health for Humanity Report
Stock Information
Webcasts & Presentations
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Health
Citizenship & Sustainability Reporting
Follow Us
Facebook
Twitter
YouTube
LinkedIn
Explore more Johnson & Johnson sites:
Australia
Argentina
Brazil
Canada
Chile
China
Colombia
Costa Rica
Ecuador
Germany
India
Italy
Japan
Mexico
New Zealand / Pacific
Paraguay
Peru
Philippines
Russia
Switzerland
German
English
French
Italian
Uruguay
United States
Venezuela
Press Release Archive
+
View Filters
All Topics
Caring & Giving
Health & Wellness
Innovation
Our Company
Our Heritage
Our Products
All Dates
Last 30 Days
Last 90 Days
Last Year
Sort by Newest
Sort by Oldest
Products & Operating Company
April 01, 2014
Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy
March 31, 2014
Johnson & Johnson Announces Acceptance Of Binding Offer From The Carlyle Group To Acquire Ortho-Clinical Diagnostics
Products & Operating Company
March 31, 2014
Janssen Expands the EXPLORER Global Cardiovascular Research Program with Three New Studies Evaluating XARELTO® in Patients at Risk for Venous Thromboembolism
March 31, 2014
Johnson & Johnson Enters Agreement to be Official Healthcare Partner of the USO
Johnson & Johnson announced it has entered a multi-year agreement to be the Official Healthcare Partner of the USO. The announcement was made today during a ceremony to mark the opening of the USO’s ...
Products & Operating Company
March 24, 2014
Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy In Treatment Of Moderate To Severe Plaque Psoriasis
Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab
Products & Operating Company
March 21, 2014
Siltuximab Receives CHMP Positive Opinion for use in the Treatment of Multicentric Castleman’s Disease, a very Rare Blood Disorder
Products & Operating Company
March 20, 2014
Janssen Investigational Treatment for Schizophrenia Shows Positive Efficacy, Delays Relapse
Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy
Products & Operating Company
March 13, 2014
New Depuy Synthes Advantage™ Provides Solutions Focused On Improving Clinical And Economic Outcomes And Patient Satisfaction
Solutions include MedTrak, Inc.’s CareSense System To Track and Analyze Patient Outcomes, Patient Satisfaction and Cost
Financial
March 12, 2014
Depuy Synthes Joint Reconstruction Introduces Two New Knee Technologies For The ATTUNE® Knee System
Financial
March 11, 2014
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
See More Press Releases